October 24, 2009 -- Boehringer Ingelheim will invest $149 million in China for new facilities including an R&D center; Simcere Pharma acquired China rights to a dual-mechanism cancer drug from OSI Pharma; California’s stem cell agency will collaborate with China’s Ministry of Science and Technology; Shanghai ChemPartner will open a European headquarters office in Denmark; BioTime presented its work on the use of stem cells as a cancer therapy at a conference; China Medical Technologies received SFDA approval for its Surface Plasmon Resonance (SPR) diagnostic technology; China Medicine Corporation registered its vascular drug in Pakistan; Sinovac Biotech was approved to distribute its swine flu vaccine in Mexico; Advanced BioMedical Technologies has completed the clinical trial of its absorbable orthopedic implant screw; Bonovo Orthopedics will distribute surgical procedure products in China for elliquence llc; and China Biologic Products was named to Forbes’ 2009 list of “200 Best under a Billion” for Asia. More details... Stock Symbols: (NYSE: SCR) (NSDQ: OSIP) (OTCBB: BTIM) (NSDQ: CMED) (OTCBB: CHME) (NYSE Amex: SVA) (OTCBB: ABMT) (OTCBB: CBPO)
